T1	PROC 46 61	Estudio fase 2b
T2	DISO 166 194	urticaria crónica espontánea
#1	AnnotatorNotes T2	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
T3	PROC 223 325	Estudio fase 2b de búsqueda de dosis, multicéntrico, aleatorizado, doble ciego, controlado con placebo
T4	PROC 331 368	investigar la eficacia y la seguridad
T5	DISO 423 451	urticaria crónica espontánea
#2	AnnotatorNotes T5	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
T6	DISO 481 497	habones crónicos
T7	DISO 524 552	urticaria crónica espontánea
#3	AnnotatorNotes T7	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
T8	PROC 801 812	Diagnóstico
#4	AnnotatorNotes T8	C0011900; Diagnosis; Diagnostic Procedure
T9	DISO 854 859	picor
#5	AnnotatorNotes T9	C0033774; Pruritus; Sign or Symptom
T10	DISO 862 869	habones
#6	AnnotatorNotes T10	C0221232; Welts; Sign or Symptom
T11	PROC 957 968	Diagnóstico
#7	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	CHEM 1010 1026	antihistamínicos
#8	AnnotatorNotes T12	C0019590; Histamine Antagonists; Organic Chemical · Pharmacologic Substance
T13	PROC 1108 1117	protocolo
#9	AnnotatorNotes T13	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T14	DISO 1219 1222	UCE
T15	DISO 1192 1211	urticarias crónicas
#10	AnnotatorNotes T15	C0263338; Chronic Urticaria; Disease or Syndrome
T16	DISO 1241 1259	enfermedad cutánea
#11	AnnotatorNotes T16	C0037274; Dermatologic disorders; Disease or Syndrome
T17	DISO 1271 1276	picor
#12	AnnotatorNotes T17	C0033774; Pruritus; Sign or Symptom
T18	PROC 1309 1321	evaluaciones
#13	AnnotatorNotes T18	C1261322; Evaluation procedure; Health Care Activity
T19	CHEM 1361 1371	omalizumab
#14	AnnotatorNotes T19	C0966225; omalizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T20	DISO 1391 1401	anafilaxia
#15	AnnotatorNotes T20	C0002792; anaphylaxis; Disease or Syndrome
T21	CHEM 372 383	ligelizumab
#16	AnnotatorNotes T21	C4041919; ligelizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T22	DISO 816 819	UCE
T23	ANAT 1252 1259	cutánea
#17	AnnotatorNotes T23	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T24	PROC 1449 1458	protocolo
#18	AnnotatorNotes T24	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T25	CHEM 129 135	QGE031
#19	AnnotatorNotes T25	C5226733; QGE-031; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T26	CHEM 385 391	QGE031
#20	AnnotatorNotes T26	C5226733; QGE-031; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T27	DISO 972 975	UCE
T28	DISO 453 456	UCE
T29	DISO 196 199	UCE
T30	PROC 584 620	consentimiento informado por escrito
#21	AnnotatorNotes T30	C0811741; Obtain informed written consent; Health Care Activity
T31	PROC 1047 1060	randomización
T32	PROC 88 125	investigar la eficacia y la seguridad
T33	Date 13 17	2017
T35	Duration 176 183	crónica
#22	AnnotatorNotes T35	C0205191; chronic; Temporal Concept
T36	LIVB 396 418	pacientes adolescentes
#23	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group | C0205653; Adolescent (age group); Age Group
T37	Duration 433 440	crónica
#24	AnnotatorNotes T37	C0205191; chronic; Temporal Concept
T38	Duration 489 497	crónicos
T39	Duration 534 541	crónica
#25	AnnotatorNotes T39	C0205191; chronic; Temporal Concept
T40	LIVB 625 635	progenitor
#26	AnnotatorNotes T40	C0030551; parent; Family Group | C0870134; Ancestor; Family Group
T41	LIVB 669 673	niño
#27	AnnotatorNotes T41	C0008059; Child; Age Group
T42	LIVB 676 713	Pacientes adolescentes de ambos sexos
#28	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group + C0001588; Adolescents, Female; Age Group + C0001589; Adolescents, Male; Age Group
T43	Age 714 736	entre ≥ 12 y < 18 años
T44	Duration 831 838	6 meses
T45	Duration 878 909	al menos 6 semanas consecutivas
T46	Duration 1203 1211	crónicas
#29	AnnotatorNotes T46	C0205191; chronic; Temporal Concept
T47	Duration 1277 1284	crónico
#30	AnnotatorNotes T47	C0205191; chronic; Temporal Concept
T49	LIVB 139 161	pacientes adolescentes
#31	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group | C0205653; Adolescent (age group); Age Group
T34	LIVB 638 649	tutor legal
#32	AnnotatorNotes T34	C0023226; Legal Guardians; Population Group
T50	Date 913 930	cualquier momento
A1	Population_data T49 Age
A2	Population_data T36 Age
A3	Population_data T41 Age
A4	Population_data T42 Age
A5	Status T9 History_of
A6	Status T10 History_of
A7	Status T19 History_of
A8	Status T20 History_of
#33	AnnotatorNotes T38	C0205191; chronic; Temporal Concept
#34	AnnotatorNotes T31	C0034656; Randomization; Research Activity
#35	AnnotatorNotes T32	C0511730; Identify product efficacy and safety issues; Health Care Activity
#36	AnnotatorNotes T4	C0511730; Identify product efficacy and safety issues; Health Care Activity
#37	AnnotatorNotes T28	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
#38	AnnotatorNotes T22	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
#39	AnnotatorNotes T27	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
#40	AnnotatorNotes T14	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
#41	AnnotatorNotes T29	C0578870; Chronic Spontaneous Urticaria; Disease or Syndrome
#42	AnnotatorNotes T6	C0263338; Chronic Urticaria; Disease or Syndrome (?)
T48	Neg_cue 1213 1218	salvo
A9	Assertion T14 Negated
R1	Experiences Arg1:T49 Arg2:T25	
R2	Has_Duration_or_Interval Arg1:T2 Arg2:T35	
R3	Has_Duration_or_Interval Arg1:T29 Arg2:T35	
R4	Experiences Arg1:T49 Arg2:T2	
R5	Experiences Arg1:T49 Arg2:T29	
R6	Experiences Arg1:T36 Arg2:T21	
R7	Experiences Arg1:T36 Arg2:T26	
R8	Experiences Arg1:T36 Arg2:T5	
R9	Experiences Arg1:T36 Arg2:T28	
R10	Has_Duration_or_Interval Arg1:T5 Arg2:T37	
R11	Has_Duration_or_Interval Arg1:T28 Arg2:T37	
R12	Has_Duration_or_Interval Arg1:T6 Arg2:T38	
R13	Has_Duration_or_Interval Arg1:T7 Arg2:T39	
T51	Observation 652 664	asentimiento
#43	AnnotatorNotes T51	C1302239; Patient consented to clinical trial; Finding (?)
R15	Has_Age Arg1:T42 Arg2:T43	
R16	Before Arg1:T8 Arg2:T44	
R17	Overlap Arg1:T22 Arg2:T9	
R18	Overlap Arg1:T22 Arg2:T10	
R19	Has_Duration_or_Interval Arg1:T10 Arg2:T45	
R20	Has_Duration_or_Interval Arg1:T9 Arg2:T45	
R21	Overlap Arg1:T10 Arg2:T50	
R22	Overlap Arg1:T9 Arg2:T50	
T52	CONC 945 954	inclusión
#44	AnnotatorNotes T52	C1512693; Inclusion; Qualitative Concept
R23	Before Arg1:T10 Arg2:T52	
R24	Before Arg1:T9 Arg2:T52	
R25	Before Arg1:T22 Arg2:T52	
R26	Before Arg1:T22 Arg2:T44	
R27	Overlap Arg1:T27 Arg2:T31	
R28	Overlap Arg1:T11 Arg2:T31	
T53	Quantifier_or_Qualifier 976 987	refractaria
#45	AnnotatorNotes T53	C0205269; Unresponsive to Treatment; Functional Concept
R29	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T53	
R30	Overlap Arg1:T27 Arg2:T12	
R31	Has_Duration_or_Interval Arg1:T15 Arg2:T46	
R32	Negation Arg1:T48 Arg2:T14	
R33	Location_of Arg1:T23 Arg2:T16	
R34	Overlap Arg1:T16 Arg2:T17	
R35	Has_Duration_or_Interval Arg1:T17 Arg2:T47	
T54	Observation 1295 1338	confundir las evaluaciones y los resultados
R36	Before Arg1:T16 Arg2:T54	
R37	Before Arg1:T17 Arg2:T54	
T55	Spec_cue 1289 1294	pueda
A10	Assertion T54 Speculated
R38	Speculation Arg1:T55 Arg2:T54	
R39	Location_of Arg1:T23 Arg2:T17	
A11	Experiencer T49 Patient
A12	Experiencer T36 Patient
A13	Experiencer T40 Family_member
A14	Experiencer T34 Other
A15	Experiencer T41 Patient
A16	Experiencer T42 Patient
